Additionally, hemin (a porphyria therapeutic agent) has been shown to upregulate GPX4 via the HO-1/NRF2 signaling pathway, thereby inhibiting oxidative stress and ferroptosis, which alleviates CIN (265). This evidence concerns the gene GPX4 and cervical squamous intraepithelial neoplasia.